{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:34:41Z","timestamp":1782884081535,"version":"3.54.5"},"reference-count":33,"publisher":"Royal Society of Chemistry (RSC)","issue":"29","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":188,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["rsc.org"],"crossmark-restriction":true},"short-container-title":["RSC Adv."],"abstract":"<jats:p>Olutasidenib is an inhibitor licensed by the FDA, indicated against mutations in isocitrate dehydrogenase-1 (IDH1).<\/jats:p>","DOI":"10.1039\/d5ra01161b","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:17:54Z","timestamp":1751966274000},"page":"23836-23844","update-policy":"https:\/\/doi.org\/10.1039\/rsc_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioanalytical method development and validation for determination of olutasidenib and its application to pharmacokinetic studies"],"prefix":"10.1039","volume":"15","author":[{"given":"Madhusudhana Reddy","family":"Nimmakayala","sequence":"first","affiliation":[{"name":"Department of Chemistry, Koneru Lakshmaiah Education Foundation, Green Fields, Vaddeswaram, Guntur, Andhra Pradesh, 522302, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuruva","family":"Rangamuni","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Koneru Lakshmaiah Education Foundation, Green Fields, Vaddeswaram, Guntur, Andhra Pradesh, 522302, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasti","family":"Surendra","sequence":"additional","affiliation":[{"name":"Department of Mechanical Engineering, Prasad V Potluri Siddhartha Institute of Technology, Kanuru, Vijayawada, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatla Murali","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Koneru Lakshmaiah Education Foundation, Green Fields, Vaddeswaram, Guntur, Andhra Pradesh, 522302, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5240-6227","authenticated-orcid":false,"given":"Deepti","family":"Kolli","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Koneru Lakshmaiah Education Foundation, Green Fields, Vaddeswaram, Guntur, Andhra Pradesh, 522302, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"292","published-online":{"date-parts":[[2025]]},"reference":[{"key":"D5RA01161B\/cit1\/1","author":"Rigel Announces U.S.","year":"2022","unstructured":"Rigel Announces U.S. ,  FDA Approval of Rezlidhia (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation ,  Rigel Pharmaceuticals, Inc. , 1 December  2022 , Retrieved 2 December, 2022"},{"key":"D5RA01161B\/cit2\/1","author":"Rigel Announces U.S.","year":"2022","unstructured":"Rigel Announces U.S. ,  FDA Approval of Rezlidhia (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation .  Rigel Pharmaceuticals , 1 December  2022 , Retrieved 2 December, 2022 \u2013 via PR Newswire"},{"key":"D5RA01161B\/cit3\/1","volume-title":"Rezlidhia-olutasidenib Capsule","year":"2022","unstructured":"Rezlidhia-olutasidenib Capsule ,  DailyMed , 13 December  2022 , Retrieved 21 January, 2023"},{"key":"D5RA01161B\/cit4\/1","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/215814Orig1s000ltr.pdf , This article incorporates text from this source, which is in the public domain"},{"key":"D5RA01161B\/cit5\/1","volume-title":"FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation","author":"U.S. Food and Drug Administration (FDA)","year":"2022","unstructured":"U.S. Food and Drug Administration (FDA) ,  FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation , 1 December,  2022 , Retrieved 20 December, 2022"},{"issue":"3","key":"D5RA01161B\/cit6\/1","volume-title":"International Nonproprietary Names for Pharmaceutical Substances (INN): Recommended INN: List 82","volume":"33","author":"World Health Organization","year":"2019","unstructured":"World Health Organization ,  International Nonproprietary Names for Pharmaceutical Substances (INN): Recommended INN: List 82 ,  WHO Drug Information ,  2019 , vol.  33 ( 3 ), hdl:10665\/330879"},{"issue":"5","key":"D5RA01161B\/cit7\/1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1351\/pac200274050835","volume":"74","author":"Thompson","year":"2008","journal-title":"Pure Appl. Chem."},{"key":"D5RA01161B\/cit8\/1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/BLCTT.S177913","volume":"9","author":"Meg\u00edas-Vericat","year":"2019","journal-title":"Blood Lymphatic Cancer"},{"key":"D5RA01161B\/cit9\/1","author":"REZLIDHIA (olutasidenib)","year":"2022","unstructured":"REZLIDHIA (olutasidenib) ,  FDA-approved for treatment of adult patients with relapsed or refractory acute myeloid leukemia , available at biologics by McKesson, December 19,  2022 , Accessed December 21, 2022"},{"key":"D5RA01161B\/cit10\/1","author":"The American Cancer Society","year":"2022","unstructured":"The American Cancer Society ,  Key Statistics for Acute Myeloid Leukemia (AML) , Revised January 12,  2022 , Accessed Aug. 1, 2022 at  https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/about\/key-statistics.html"},{"key":"D5RA01161B\/cit11\/1","author":"Leukaemia Care","year":"2019","unstructured":"Leukaemia Care ,  Relapse in Acute Myeloid Leukaemia (AML) , Version 3. Reviewed October 2021,  2019 , Accessed Dec 2, 2021 at  https:\/\/media.leukaemiacare.org.uk\/wpcontent\/uploads\/Relapse-in-Acute-Myeloid-Leukaemia-AML-Web-Version.pdf"},{"issue":"3","key":"D5RA01161B\/cit12\/1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"D5RA01161B\/cit13\/1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.9734\/bpi\/psnid\/v2\/4023","volume-title":"Pharmaceutical Science: New Insights and Developments","author":"Sankar","year":"2025","unstructured":"P. R.Sankar ,  K. H.Sri ,  C. V. P.Rao  and  G.Jhansi ,  Stability Indicating RP-HPLC Method for the Estimation of Olutasidenib in Bulk Pharmaceutical Formulations ,  Pharmaceutical Science: New Insights and Developments ,  2025 ,  pp. 35\u201369 ,  10.9734\/bpi\/psnid\/v2\/4023"},{"issue":"3","key":"D5RA01161B\/cit14\/1","first-page":"309","volume":"46","author":"Trufelli","year":"2011","journal-title":"J. Mass Spectrom."},{"issue":"2","key":"D5RA01161B\/cit15\/1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/10408347.2014.980775","volume":"46","author":"Panuwet","year":"2016","journal-title":"Crit. Rev. Anal. Chem."},{"issue":"12","key":"D5RA01161B\/cit16\/1","doi-asserted-by":"crossref","first-page":"e4956","DOI":"10.1002\/bmc.4956","volume":"34","author":"Chaves","year":"2020","journal-title":"Biomed. Chromatogr."},{"issue":"17","key":"D5RA01161B\/cit17\/1","first-page":"4267","volume":"411","author":"Vandermeer","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"D5RA01161B\/cit18\/1","author":"U.S. Department of Health and Human Services","year":"2018","unstructured":"U.S. Department of Health and Human Services ,  Food and Drug Admnistration  and  Center for Drug Evaluation and Research ,  Guidance for industry: Bioanalytical method validation ,  2018 ,  https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry"},{"key":"D5RA01161B\/cit19\/1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1248\/cpb.c18-00840","volume":"67","author":"Sakurai","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"D5RA01161B\/cit20\/1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1248\/cpb.c21-00142","volume":"69","author":"Belabbas","year":"2021","journal-title":"Chem. Pharm. Bull."},{"key":"D5RA01161B\/cit21\/1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1248\/cpb.56.28","volume":"56","author":"Srinubabu","year":"2008","journal-title":"Chem. Pharm. Bull."},{"key":"D5RA01161B\/cit22\/1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1248\/cpb.59.1083","volume":"59","author":"Ku","year":"2011","journal-title":"Chem. Pharm. Bull."},{"key":"D5RA01161B\/cit23\/1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1248\/cpb.56.413","volume":"56","author":"Narasimhan","year":"2008","journal-title":"Chem. Pharm. Bull."},{"key":"D5RA01161B\/cit24\/1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0165-9936(99)00150-8","volume":"18","author":"Wood","year":"2005","journal-title":"Trends Anal. Chem."},{"issue":"14","key":"D5RA01161B\/cit25\/1","first-page":"53","volume":"5","author":"Thulaseedhar","year":"2022","journal-title":"Int. J. Appl. Pharm. Sci."},{"key":"D5RA01161B\/cit26\/1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jala.2010.02.001","volume":"15","author":"Chiu","year":"2010","journal-title":"J. Assoc. Lab. Autom."},{"key":"D5RA01161B\/cit27\/1","volume-title":"Validation of Analytical Methods: Methodology","author":"International Conference on Harmonization (ICH)","year":"1996","unstructured":"International Conference on Harmonization (ICH) ,  Validation of Analytical Methods: Methodology , ICH Q2B,  1996"},{"key":"D5RA01161B\/cit28\/1","volume-title":"The Fitness for Purpose of Analytical Methods\u2014A Laboratory Guide to Method Validation and Related Topics","author":"EURACHEM","year":"1998","unstructured":"EURACHEM ,  The Fitness for Purpose of Analytical Methods\u2014A Laboratory Guide to Method Validation and Related Topics ,  1998"},{"key":"D5RA01161B\/cit29\/1","first-page":"3","volume":"5","author":"Lalit","year":"2014","journal-title":"Pharm. Anal. Acta"},{"key":"D5RA01161B\/cit30\/1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1351\/pac200274050835","volume":"74","author":"Thompson","year":"2002","journal-title":"Pure Appl. Chem."},{"key":"D5RA01161B\/cit31\/1","first-page":"146","volume":"74","author":"Anhang","year":"2004","journal-title":"Toxichem Krimtech"},{"issue":"2","key":"D5RA01161B\/cit32\/1","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.26452\/ijrps.v11i2.2172","volume":"11","author":"Amar Babu","year":"2020","journal-title":"Int. J. Res. Pharm. Sci."},{"key":"D5RA01161B\/cit33\/1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s42452-021-04219-x","volume":"3","author":"Prabhakara Rao","year":"2021","journal-title":"SN Appl. Sci."}],"container-title":["RSC Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/pubs.rsc.org\/en\/content\/articlepdf\/2025\/RA\/D5RA01161B","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:23:22Z","timestamp":1782879802000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.rsc.org\/ra\/article\/15\/29\/23836-23844\/906297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":33,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1039\/d5ra01161b","relation":{},"ISSN":["2046-2069"],"issn-type":[{"value":"2046-2069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}